Seres Therapeutics
MCRB
91 hedge funds and large institutions have $198M invested in Seres Therapeutics in 2019 Q2 according to their latest regulatory filings, with 24 funds opening new positions, 33 increasing their positions, 14 reducing their positions, and 13 closing their positions.
539% more call options, than puts
Call options by funds: $1.82M | Put options by funds: $284K
136% more repeat investments, than reductions
Existing positions increased: 33 | Existing positions reduced: 14
85% more first-time investments, than exits
New positions opened: 24 | Existing positions closed: 13
11% more funds holding
Funds holding: 82 → 91 (+9)
0.43% more ownership
Funds ownership: 4.11% → 4.54% (+0.43%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
15% less capital invested
Capital invested by funds: $232M → $198M (-$33.8M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FP
Flagship Pioneering
Cambridge,
Massachusetts
|
+$42.2M |
| 2 |
Sumitomo Mitsui Trust Group
Minato-Ku, Tokyo,
Japan
|
+$19.2M |
| 3 |
NAMA
Nikko Asset Management Americas
New York
|
+$19.1M |
| 4 |
PA
Perceptive Advisors
New York
|
+$11.9M |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
+$10.8M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$614K |
| 2 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
-$589K |
| 3 |
Schroder Investment Management Group
London,
United Kingdom
|
-$469K |
| 4 |
Swiss National Bank
Zurich,
Switzerland
|
-$248K |
| 5 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$182K |
MCRB Hedge Fund Activity: Q2 2019 in Review
91 of the 4,604 institutional investors tracked by Wall St. Rank reported a position in Seres Therapeutics (MCRB) for Q2 2019, worth a combined $198M — down 15% from $232M a quarter earlier.
Buyers outnumbered sellers: 24 funds opened new MCRB positions and 13 closed out — a net gain of 11 holders — while 33 added to existing stakes and 14 trimmed.
The largest buyer was Flagship Pioneering, adding an estimated $42.2M. The largest seller was Morgan Stanley, cutting an estimated $614K.
- 91 institutional investors held Seres Therapeutics (MCRB) as of Q2 2019, up from 82 in Q1 2019.
- Funds reported $198M of Seres Therapeutics stock for Q2 2019, down 15% quarter-over-quarter.
- 24 funds opened new Seres Therapeutics positions in Q2 2019 and 13 closed out, a net change of +11 holders.
- The largest Seres Therapeutics buyer in Q2 2019 was Flagship Pioneering, an estimated $42.2M added.
- The largest Seres Therapeutics seller in Q2 2019 was Morgan Stanley, an estimated $614K sold.
Based on aggregated 13F filings for Q2 2019.